Immunodiagnostic Systems Holdings PLC provided revenues guidance for the financial year ended 31 March 2018. Unaudited Group revenue is expected to be approximately £37.9 million, a decrease of 5% on the previous year (and a decline of 8% at constant exchange rates "CER"). The majority of the decline was due to the loss of royalty income from a major customer, as communicated previously. Revenues in the Laboratory business (comprising the Automated and Manual business units) are expected to be £35.2 million, unchanged on the previous year at CER, with growth in the automated business offsetting declines in the manual business.